Nathan M. Hager

2 papers in the library · publishing 2025-2026

Papers

Lifetime psychedelic use and opioid use disorder severity in a National Survey: the roles of psychedelic type and mental health.

Addictive behaviors June 1, 2026 Sebastian Ehmann, Nathan M. Hager, Paul S. Regier et al.

Using data from the 2023 U.S. National Survey on Drug Use and Health, lifetime use of mescaline or peyote was associated with lower opioid use disorder severity, while lifetime use of LSD, psilocybin, MDMA, or DMT was associated with higher severity. The link between mescaline/peyote use and lower severity appeared only among adults with high mental health impairment. The findings suggest that different types of psychedelic use have divergent relationships with opioid use disorder severity, and that mental health status may influence these associations.

DOI: 10.1016/j.addbeh.2026.108652 Full text Mescaline Opioid use disorder Peyote Mental health impairment +1

Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health–Dependent Associations in a National Survey

PsyArXiv November 2, 2025 Sebastian Ehmann, Nathan M. Hager, Paul S. Regier et al. preprint

Among a national sample of US adults, lifetime psychedelic use is associated with lower severity of opioid use disorder, but this relationship depends on broader substance-use patterns and mental health. The protective association appears specific to certain substance-use profiles and is mediated by mental health status. The findings suggest that psychedelic use alone does not uniformly reduce opioid use disorder severity; rather, the context of other substance use and psychological well-being shapes the association.

DOI: 10.31234/osf.io/jd2rk_v1 Opioid use disorder Substance use disorder Psychedelics Psychedelic use +11